Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...
Asia News Network2d
Brunei introduces pneumococcal vaccine for infants, children
With this addition, the Sultanate's immunisation programme now includes 12 vaccines to prevent 12 vaccine-preventable diseases. Vaccinations under the programme are provided free of charge at Maternal ...
Daily3d
Centers for Disease Control and Prevention (CDC) Lowers Pneumococcal Vaccination Age to 50
Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...
The Pharma Letter3d
Uvax Bio appoints Kevin O’Neill as interim chief executive
Uvax Bio, a privately held vaccine developer founded in 2018 as a spin-off from Scripps Research, has appointed chief ...
Zacks.com on MSN3d
Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 View
Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...